CoChat

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Yabe, Daisuke, Nakamura, Jiro, Kaneto, Hideaki, Deenadayalan, Srikanth, Navarria, Andrea, Gislum, Mette, Inagaki, Nobuya, Arisaka, T, Asakura, T, Azuma, N, Fukuda, S, Fukushima, Y, Harada, N, Inoue, S, Ishida, H, Ishii, H, Ishikawa, S, Jinnouchi, H, Kaneko, S, Kanno, K, Kato, M, Kato, Y, Kawada, T, Kim, H, Kiyosue, A, Matsuoka, O, Miho, O, Nakamoto, S, Nakamura, S, Nakanishi, S, Nishimura, H, Numata, A, Ohama, T, Okabe, T, Okuguchi, F, Osonoi, T, Sasaki, T, Seino, H, Shin, K, Shiraiwa, T, Sugiura, T, Wada, S, Yamauchi, A · 2020 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.

Abstract

BACKGROUND New glucose-lowering medications need to be investigated in east Asian populations, as the clinical characteristics of type 2 diabetes differ between western and east Asian patients. The PIONEER 10 study aimed to evaluate the safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes. METHODS PIONEER 10 was an open-label, randomised, active-controlled, phase 3a trial done at 36 sites (clinics and university hospitals) in Japan. Patients aged 20 years and older with uncontrolled type 2 diabetes were randomly assigned (2:2:2:1) to receive once-daily oral semaglutide 3 mg, 7 mg, or 14 mg, or once-weekly subcutaneous dulaglutide 0·75 mg for 52 weeks, as an add-on to their background medication. The primary endpoint was the number of treatment-emergent adverse events over 57 weeks. Supportive secondary endpoints (not controlled for multiplicity) included mean change from baseline in HbA1c and bodyweight at 52 weeks. This trial is registered with ClinicalTrials.gov, NCT03015220. FINDINGS Between Jan 10, and May 30, 2017, 492 patients were screened and 458 were randomly assigned to oral semaglutide 3 mg (n=131), 7 mg (n=132), or 14 mg (n=130), or dulaglutide 0·75 mg (n=65). 448 (98%) patients completed the trial. Adverse events occurred in 101 (77%) of 131 patients with oral semaglutide 3 mg, 106 (80%) of 132 with oral semaglutide 7 mg, 111 (85%) of 130 with oral semaglutide 14 mg, and 53 (82%) of 65 with dulaglutide. The most com…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(20)30074-7

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 29 references

Research works printed but not linked: 1

  1. Kaku, 2018, Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial, Diabetes Obes Metab, 20, 1202, 10.1111/dom.13218 · DOI · Paper page

Cited by

See all 231

Metadata

Authors
Yabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., Fukuda, S., Fukushima, Y., Harada, N., Inoue, S., Ishida, H., Ishii, H., Ishikawa, S., Jinnouchi, H., Kaneko, S., Kanno, K., Kato, M., Kato, Y., Kawada, T., Kim, H., Kiyosue, A., Matsuoka, O., Miho, O., Nakamoto, S., Nakamura, S., Nakanishi, S., Nishimura, H., Numata, A., Ohama, T., Okabe, T., Okuguchi, F., Osonoi, T., Sasaki, T., Seino, H., Shin, K., Shiraiwa, T., Sugiura, T., Wada, S., & Yamauchi, A.
Affiliations
  • Gifu University (JP)
  • Aichi Medical University (JP)
  • Kawasaki Medical School (JP)
  • Novo Nordisk (Denmark) (DK)
  • Kyoto University (JP)
Corresponding author
Yabe, Daisuke
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2020-05
Volume
8
Issue
5
Pages
392-406
ISSN
2213-8587 (ISSN-L)
OpenAlex
W3018053472
Cited by
210
References
30
Citations by year
2026: 24 · 2025: 44 · 2024: 42 · 2023: 24 · 2022: 26 · 2021: 22 · 2020: 27
FWCI
18.67
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
oral semaglutide, dulaglutide, type 2 diabetes, Japanese patients, GLP-1 receptor agonists, HbA1c, body weight, gastrointestinal adverse effects, constipation, nausea, treatment discontinuation, adverse events, dose comparison, adjunctive therapy, East Asian populations, Pioneer 10
MeSH terms
Semaglutide, Administration, Oral, Adult, Aged, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Immunoglobulin Fc Fragments, Male, Middle Aged, Recombinant Fusion Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. https://app.cochat.ai/papers/10.1016/s2213-8587(20)30074-7
The paper
Yabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., Fukuda, S., Fukushima, Y., Harada, N., Inoue, S., Ishida, H., Ishii, H., Ishikawa, S., Jinnouchi, H., Kaneko, S., . . . Yamauchi, A. (2020). Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(20)30074-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.